Document:

Exhibit 10.5

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

SUPPLY AGREEMENT
ON GONADORELIN ACETATE

 

This Agreement is made
as of September 26, 2011 (the “Effective Date”) between Bachem AG, an entity organized under the laws of
Switzerland, with its principal place of business at Hauptstrasse 144, CH-4416 Bubendorf, Switzerland (“Bachem”),
and Parnell Manufacturing Pty Ltd, an entity organized under the laws of Australia, with its principal place of business at Unit
4 Century Estate, 476 Gardeners Road, Alexandria NSW 2015, Australia (“Parnell”).

 

PREAMBLE

 

WHEREAS, Bachem is
engaged in the manufacturing and sale of peptidic active pharmaceutical ingredients (APIs).

 

WHEREAS, Gonadorelin
Acetate is a generic active pharmaceutical ingredient.

 

WHEREAS, Parnell desires
to purchase from Bachem on a non-exclusive basis Gonadorelin Acetate (the Product”) and subject to section 2.05 Bachem
desires to sell on a non-exclusive basis Gonadorelin Acetate to Parnell upon the terms and conditions herein contained.

 

THEREFORE, the Parties
hereto agree as follows:

 

Article
I

DEFINITIONS

 

Unless the context
otherwise requires, the following terms as used in this agreement shall have the following meanings (such meanings to be equally
applicable in the singular and plural forms of the terms defined):

 

“Agreement”
means this Supply Agreement including its Exhibits.

 

“Certificate
of Analysis” means a certificate in writing that certifies (a) the conformity of the Product to the Specifications;
(b) the Product meets the requirements of Ph. Eur. and (c) manufacturing and control records were reviewed by Bachem
in accordance with all Good Manufacturing Practices (“cGMP”) or similar standards of Competent Authorities.

 

“Competent
Authorities” means the entities in the applicable countries responsible for the regulation of medicinal products intended
for human use.

 

“Confidential
Information” means all such information, including the Specifications all technical and/or proprietary information relating
to the Product and Parnell’s Products or the production process for the Product and Parnell’s Products, information
relating to the marketing of, customers for, and sales and pricing of the Product and Parnell’s Products, and all other written
information clearly identified as “Confidential” when submitted by the disclosing Party to the receiving Party.

 

“Exhibit”
means an exhibit annexed to and forming part of this Agreement.

 

    	 

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

“FDA”
means the United States Food and Drug Administration.

 

‘Initial Term”
means the first full seven (7) calendar years following the Effective Date.

 

“Letter of
Access” means a confirmation issued by the Drug Master File holder in the form as set out in ***which grants the access
to the respective Drug Master File.

 

“Losses”
means any claim, action, demand, suit, proceeding, payment, damage, loss, cost or expense (including reasonable attorneys’
fees and reasonable costs of investigation incurred in defending against any such claim, action, demand, suit or proceeding therefore).

 

“Parnell’s
Products” means Parnell’s veterinary medications or formulas, including, but not limited to, those in any manner
arising or resulting from the use of the Product in connection with the above medications.

 

“Party”
or “Parties” shall mean Bachem or Parnell, individually or collectively as the context requires.

 

“Product”
means Gonadorelin Acetate as described more detailed in Exhibit C of this Agreement.

 

“Quality Assurance
Plan” means the plan, attached hereto as Exhibit B, prepared by Parnell and Bachem, the purpose of which is to measure
the conformity of the Product hereunder to the Specifications.

 

“Shipment”
means each individual group of the Product received by Parnell from Bachem.

 

“Specifications”
means the specifications for the Product, as more specifically described in Exhibit C of this Agreement.

 

Article
II

MANUFACTURE AND SALE

 

Section 2.01.         Agreement
to Supply Product. Subject to the terms and conditions of this Agreement, Bachem agrees to sell the Product on a non-exclusive
basis to Parnell in accordance with the terms hereof and for the duration of this Agreement.

 

Section 2.02.         Specifications.
The Specifications for the Product are set forth in Exhibit C. In the event the Competent Authority shall suggest or mandate
any change or revision to the Product, such that the Specifications would no longer comply with such suggestion or mandate, the
Parties shall work together in good faith to develop revised Specifications that meet all changes or revisions suggested or mandated
by the Competent Authority and Exhibit C shall be amended to set forth the new Specifications. If the Parties cannot come
to agreement on new Specifications within *** of the effective date of such suggestion or mandate by the Competent Authority, either
Party shall have the right to terminate this Agreement in accordance with Section 7.02(c).

 

    	2

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

Section 2.03.         Bachem’s
Responsibility. Bachem’s responsibility shall be to provide the Product meeting the Specifications in accordance
with the terms and provisions of this Agreement. The suitability of the Specifications and/or of the Product for use in Parnell’s
Products is wholly the responsibility of Parnell, and Parnell shall fully indemnify, defend and hold Bachem harmless from any resulting
Losses except for those Losses incurred by Parnell for reasons set forth in Section 5.02 herein.

 

Section 2.04.         Letter
of Access to the respective Drug Master Files. Bachem shall grant to Parnell an irrevocable Letter of Access to the respective
Drug Master Files.

 

Section 2.05.         Limited
Letter of Access to Third Parties. Notwithstanding Section 2.04 of this Agreement for the first five (5) years upon
Parnell’s marketing authorization for Parnell’s Product in the USA being granted by the FDA and ***, Bachem shall not
grant any Letter of Access to the US Drug Master File for Gonadorelin Acetate to any third party. It is acknowledged by the Parties,
that this Section 2.05 is limited to veterinary application of Gonadorelin Acetate in the USA only and this Section 2.05
is not applicable for other applications of Gonadorelin Acetate such as but not limited to human health application and this Section 2.05
is not applicable for any other country than the United States of America.

 

Section 2.06.         Compliance
with Statutory and Regulatory Requirements. Parnell shall be fully responsible for compliance with any and all statutes,
laws, ordinances, and regulations relating to the design, production, and sale of Parnell’s Products, as well as for design,
production, and sale of any of Parnell’s Products.

 

Article
III

PURCHASE

 

Section 3.01.         Agreement
to Purchase. Subject to the terms and conditions of this Agreement, Parnell agrees to purchase at least *** of the Product
within the Initial Term.

 

Section 3.02.         Forecast
of Product Required. On a *** Parnell shall provide to Bachem a *** forecast for the Product.

 

Section 3.03.         Lead-time
for Orders. From time to time, Parnell shall issue a purchase order for Product to Bachem and such purchase orders shall
be according to the forecasted quantities as per Section 3.02. Lead-time for such purchase orders are *** or any other lead-time
as mutually agreed by the Parties as of the day of the purchase order placed.

 

Section 3.04.         Delivery
and Payment. Price, delivery conditions and payment terms are set forth on Exhibit A annexed hereto. The Product will
be shipped *** Parnell’s warehouse in Australia. ***Price Adjustment. The Parties acknowledge that the agreed
price as set forth in Exhibit A shall be a fixed price for the term of this Agreement Notwithstanding this, the Parties acknowledge
and agree that the Price may be adjusted according to the rules as defined in Exhibit A – Paragraph B.

 

Section 3.05.         Purchase
Forms. In ordering and delivering, the Parties shall use their standard ordering, invoicing, acknowledgment and/or shipping
forms.

 

    	3

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

Section 3.06.         Confirmation.
Bachem shall confirm each purchase order within five (5) working days from the date of receipt of a purchase order.

 

Article
IV

WARRANTY AND REJECTION

 

Section 4.01.         Bachem
Warranty. Bachem represents and warrants to Parnell that (a) the Product delivered pursuant to this Agreement shall
comply with the Specifications; (b) at the time of manufacture the Product shall be free from defects in material workmanship
and design (other than design furnished by Parnell); (c) it has, and at all times during the term of this Agreement shall
have, the right to manufacture and sell the Product; and (d) the Product complies with all applicable federal, state or municipal
statutes, laws, rules or regulations, including those relating to the environment, food or drugs and occupational health and safety,
including, without limitation, those enforced or promulgated by the FDA or other Competent Authority. BACHEM MAKES NO OTHER WARRANTIES
OF ANY OTHER KIND, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY OR FITNESS OF THE PRODUCTS FOR ANY PURPOSE, AND
BACHEM EXPRESSLY DISCLAIMS ANY SUCH OTHER WARRANTIES WITH RESPECT TO THE PRODUCT, EITHER EXPRESSED OR IMPLIED.

 

Section 4.02.         Rejection
of the Product for Failure to Conform to the Specifications. Bachem shall conduct all necessary quality assurance tests
to ensure that any Shipments of Product conforms to the relevant Specifications prior to delivery to Parnell. Parnell shall have
thirty (30) days after the receipt of any Shipment (the “Testing Period”) to subject such Shipment, to determine
conformity with the Specifications, and whether or not the Product is free from defects in workmanship or materials, and manufactured
according to GMP. If testing shows a failure to meet the relevant Specifications, or that the Product is not free from defects
in workmanship or materials, Parnell shall provide written notice to Bachem immediately (each such notice, a “Failure
Notice”) and the Parties shall mutually agree whether the entire Shipment, or any portion thereof, shall be returned
to Bachem at Bachem’s initial cost and expense, provided that notice of nonconformity is received by Bachem from Parnell
within ten (10) days after the end of the Testing Period. The Parties shall mutually agree if (i) Bachem shall deliver replacement
Product (to be delivered as soon as reasonably practicable) or (ii) Parnell shall promptly receive full credit from Bachem
for the defective Product. If Parnell does not notify Bachem of the non-conformity of the Product within ten (10) days after the
end of the Testing Period, the Product shall be deemed to be accepted.

 

Should there be a discrepancy
between Parnell’s test results and the results of testing performed by Bachem, such discrepancies shall be finally resolved
by testing performed by an independent third party mutually agreed upon by Parnell and Bachem. The costs of such testing shall
be borne by the Party against whom the discrepancy is resolved. In the event the Product has been previously returned to Bachem
and an independent third party determines that the Product meets the Specifications, Parnell shall be responsible for all costs
associated with the return of the Product to Bachem,

 

    	4

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

Section 4.03.         Inspections.
Bachem shall permit Parnell to make FDA-type inspections at its plants to satisfy itself that Bachem manufactures the Product according
to manufacturing practices appropriate for the Product that are consistent with FDA standards and requirements and standards and
requirements of other Competent Authorities. Such inspections may include review of manufacturing practices and laboratory practices.
Parnell shall have the right at any time during normal business hours during the term of this Agreement, upon *** prior written
notice, to inspect Bachem’s facilities. Parnell shall have the right to inspect Bachem’s facilities upon *** on a ***
by Bachem of any of the terms and conditions of this Agreement.

 

Article
V

LIABILITY AND INDEMNIFICATION

 

Section 5.01.         Parnell
Indemnification. Parnell agrees to indemnify, defend and hold Bachem harmless from and against any Losses that may be incurred
or suffered by Bachem in connection with a claim, action or proceeding made or brought by a third party as a result of the use
or sale of Parnell’s Products, except for Losses incurred as a result of (a) the failure of the Product to meet or conform
to the Specifications and (b) breach of Bachem’s representations, warranties or any covenants or agreements contained
herein.

 

Section 5.02.         Bachem’s
Indemnification. Bachem agrees to indemnify, defend and hold Parnell harmless from and against any Losses that may be incurred
or suffered by Parnell in connection with a claim, action or proceeding made or brought by a third party as a result of any Losses
relating to or arising out of (a) any infringement or claim of infringement of any patent, trademark or other intellectual
property rights, based on the manufacture, sale or distribution of the Product furnished hereunder; (b) the failure of the
Product to meet the Specifications; (c) breach of Bachem’s representations, warranties or any covenants or agreements
contained herein; and (d) any gross negligence or willful misconduct by Bachem in the manufacture, storage, packaging, or
shipping of Product.

 

Section 5.03.         Limitation
of Losses. Except for each Party’s obligations of confidentiality and indemnification contained in this Agreement,
neither Party shall be liable for consequential damages including, without limitation, loss of profits or indirect loss arising
out of or in any way related to this Agreement.

 

Section 5.04.         Indemnity
Procedure. Each indemnified Party agrees to give the indemnifying Party prompt written notice of any matter upon which
such indemnified Party intends to base a claim for indemnification (an “Indemnity Claim”) under this Article V.
The indemnifying Party shall have the right to participate jointly with the indemnified Party in the indemnified Party’s
defense, settlement or other disposition of any Indemnity Claim. With respect to any Indemnity Claim relating solely to the payment
of money damages which could not result in the indemnified Party’s becoming subject to injunctive or other equitable relief
or otherwise adversely affect the business of the indemnified Party in any manner, and as to which the indemnifying Party shall
have acknowledged in writing the obligation to indemnify the indemnified Party hereunder, the indemnifying Party shall have the
sole right to defend, settle or otherwise dispose of such Indemnity Claim, on such terms as the indemnifying Party, in its sole
discretion, shall deem appropriate, provided that the indemnifying Party shall provide reasonable evidence of its ability to pay
any damages claimed and with respect to any such settlement shall have obtained the written release of the indemnified Party from
the Indemnity Claim. The indemnifying Party shall obtain the written consent of the indemnified Party, which shall not be unreasonably
withheld, prior to ceasing to defend, settling or otherwise disposing of any Indemnity Claim if as a result thereof the indemnified
Party would become subject to injunctive or other equitable relief or the business of the indemnified Party would be adversely
affected in any manner.

 

    	5

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

Article
VI

CONFIDENTIALITY

 

Section 6.01.         Confidential
Information. Both Parties acknowledge that it will be necessary for each Party to disclose Confidential Information to
the other Party.

 

Section 6.02.         Maintenance
of Confidential Information.

 

(a)          Each
Party covenants and agrees to take all necessary steps to (i) hold in strict confidence any and all such Confidential Information
received from the other Party and shall not disclose it to anyone or use it for its own benefit or the benefit of others, except
within each Party’s own organization, and only to those of its employees, consultants, Parnell’s sub-contractors and
Purchaser’s licensees who shall be bound by confidentiality and non-use commitments no less restrictive than those of this
Agreement, and/or who are designated by each respective Party to evaluate the Confidential Information for necessary business purposes
(ii) prohibit the Confidential Information from being published in any form, without the prior express written consent of
the other Party.

 

(b)          The
foregoing obligations, however, shall not apply to information or data that (i) at the time of or after disclosure, is published,
known publicly or becomes part of the public domain through no fault of either Party; (ii) prior to disclosure, is known by
the receiving Party as evidenced by its records maintained in the ordinary course of business; (iii) information which has
been or is disclosed to the receiving Party without any obligation of confidentiality from a third party not having a contractual
relationship with the disclosing Party or which is independently developed by the receiving Party without use of the disclosing
Party’s Confidential Information; (iv) is required by law to be disclosed, provided that each Party shall undertake
its best efforts to maintain the confidentiality of such information; or (v) is disclosed in connection with the filing with,
or approval, certification or endorsement from, any governmental body or medical protocol.

 

(c)          The
mutual obligations of confidentiality under this Article VI shall survive the expiration or earlier termination of this Agreement
for a period of ten years after the expiration or earlier termination.

 

Article
VII

TERM AND TERMINATION

 

Section 7.01.         Term.
This Agreement shall become effective on the Effective Date and shall be valid for an initial period of seven (7) full calendar
years thereafter (the “Initial Term”). This Agreement shall not be automatically extended beyond the Initial
Term but the Parties shall commence negotiations on the terms of a renewed supply agreement twenty-four (24) months prior to the
end of the Initial Term or upon the supply of five (5) kg kilogram of Product whatever comes first.

 

    	6

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

Section 7.02.         Termination.
This Agreement may be terminated immediately by written notice at the option of either Party if:

 

(a)          if
the other Party materially breaches this Agreement and fails to remedy such default within *** after notice thereof from the terminating
Party;

 

(b)          either
Party by voluntary or involuntary action goes into liquidation or receivership; or dissolves or files a petition for bankruptcy
or reorganization or for suspension of payments or is adjudicated bankrupt, becomes insolvent or assigns or makes any composition
of its assets for the benefit of creditors;

 

(c)          as
set forth in Section 2.02 of this Agreement

 

(d)          Bachem in the event that Parnell according to Section 3.04 is substantially and repeatedly late with
its payment to Bachem.

 

Section 7.03.         Effect
of Termination. The termination of this Agreement shall be without prejudice to the right of the Parties to claim damages
or indemnification or any other accrued right under this Agreement and the Exhibits hereunder. Regardless of any termination (i) by
Bachem pursuant to Section 7.02(a) and/or Section 7.02(d) and the defaulting Party is Parnell or (ii) by Parnell
pursuant to Section 7.02 (b) or Section 7.02(c) the provisions of this Agreement shall continue to apply with respect
to the Parties’ respective rights and obligations in relation to any purchase order made by Parnell prior to such termination
Parnell’s obligation to make payment for such Products.

 

Article
VIII

MISCELLANEOUS

 

Section 8.01.         Force
Majeure. Neither Party shall be liable for delay or failure to perform its obligations hereunder due to any contingency
directly impacting such Party’s delay or failure to perform and beyond its reasonable control, after reasonable efforts to
exercise such control, including, but not limited to war (declared or undeclared), riot, political insurrection, rebellion, revolution,
acts or orders of or expropriation by any government (whether de facto or de jure), prohibition of the import or export of the
Product, inability to procure or shortage of Bachem’s of necessary materials, equipment or production facilities, quarantine
restrictions, fuel shortage, strike, lock-out or other labor troubles which interfere with the manufacture, sale or transportation
of the Product or with the supply of raw materials necessary for their production, or fire, flood, explosion, earthquake, tornadoes
or other natural events. The Party affected by such event of force majeure shall not later than seven (7) days after the commencement
of such event give the other Party notice of the event and shall use all reasonable means to resume full performance of its obligations
under this Agreement as soon as commercially possible.

 

Section 8.02.         Governing
Law, Dispute Resolution. This Agreement is governed by and shall be construed and interpreted in accordance with the laws
of ***. All disputes arising in connection with this Agreement, which cannot be settled amicably, shall be resolved by *** by a
***.

 

    	7

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

  

Section 8.03.         Assignment.
This Agreement may not be assigned by either Party without the prior written consent of the other.

 

Section 8.04.         Notices.
Any notice, requests, delivery, approval or consent required or permitted to be given under this Agreement shall be in writing
and shall be deemed to have been sufficiently given if delivered in person, transmitted by telecopy or registered mail to the Party
to whom it is directed at its address shown below or such other address as such Party shall have last given by notice to the other
Party.

 

If to Bachem:

 

If to Parnell:

 

Section 8.05.         Entire
Agreement. This Agreement and attachments contain the entire understanding between the Parties and supersedes any and all
prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained
in this Agreement. No amendments, changes, modifications or alterations of the terms and conditions of this Agreement shall be
binding upon either Party, unless in writing and signed by an authorized representative of each Party. Any terms and conditions,
or any other provision in any purchase order used by Parnell or acknowledgment document used by Bachem which may be different or
inconsistent with this Agreement shall be entirely inapplicable, and this Agreement shall take precedence over all such other releases,
acknowledgments, or other documents which may be used in the implementation or the administration of this Agreement.

 

Section 8.06.         Waiver.
The waiver by any Party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of
any subsequent breach.

 

Section 8.07.         Independent
Contractors. Nothing in this Agreement shall operate to or be construed or interpreted as to render the Parties hereto
as other than independent contractors, nor shall anything in this Agreement operate or be construed or interpreted as to render
either Party, or any of such Party’s employees, agents or contractors, to be employees, agents, associates, joint ventures
or partners of the other Party.

 

Section 8.08.         Severability.
In the event that individual provisions of this Agreement become wholly or partially invalid as evidenced by a ruling of a court
of competent jurisdiction, the effectiveness of the remaining rulings shall not be affected, to the extent severable. The Parties
undertake in good faith to replace an invalid provision by a valid one which most closely corresponds with the economic intention
of the invalid ruling.

 

Section 8.09.         Captions.
The captions at the beginning of each section hereof are for the convenience of the Parties and shall in no event be construed
to alter or in any way affect the meaning of the substantive text of this Agreement.

 

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be duly executed by their authorized representatives on the Effective Date.

 

	Bachem AG	 	 
	Bubendorf,	 	 	 
	 	 	 	 

 

    	8

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

	By:	  /s/ Anne-Kathrin Stoller	 	By:	 /s/ Franziska Arnhold
	 	Dr. Anne-Kathrin Stoller	 	 	Dr. Franziska Arnhold
	 	Vice President Marketing & Sales	 	 	Director Business Development &
	 	 	 	 	Project Management

 

	Parnell Manufacturing Pty Ltd	 	 
	Alexandria,	 	 	 
	 	 	 	 

	By:	/s/ Robert Joseph	 	 
	 	Robert Joseph	 	 
	 	Chief Executive Officer	 	 

 

    	9

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

List of Exhibits:

 

Exhibit A: Prices, Incoterms, Payment Terms

Exhibit B: Quality Assurance Plan

Exhibit C: Specification

 

***

 

    	10

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

	
        Parnell/Bachem

        Agreement for Manufacture

        and Supply
	
        Exhibit A

        Prices, Incoterms,

        Payment Terms
	Gonadorelin

Acetate

A.           ***Price
for the Product

 

The Price shall be *** of Product. Except
as otherwise expressly provided in this Agreement, the Price specified in each purchase order accepted by Bachem shall be full
compensation for all manufacturing and characterization activities and associated material thereof.

 

B.           Price
Adjustment

 

During the term of this Agreement, if Bachem
wishes to increase the price for the Product as specified in this Exhibit A - Paragraph A by more than 2%, Parnell
may request to renegotiate the price with Bachem. Such request may not occur more than *** and must set out the reasons for such
request to increase the price including one of the following events:

 

(i)          the
*** of the price changes by ***

 

(ii)         Bachem’s
***.

 

Bachem will notify Parnell of any change
in the price or a request to renegotiate the price by more than 2% not later than ***of the prior year to the increase taking effect
which will occur on *** of the proceeding calendar year. On receipt of such notification, the Parties shall seek in good faith,
to agree any adjustment to the price, based on ***.

 

C.           Delivery

 

The delivery of the Product according to
Section 3.06 shall be *** to Parnell’s warehouse in Australia.

 

D.           Payment
terms

 

Payment terms: The payment terms shall
be *** from the date of ***.

 

***

 

    	A-1

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

Parnell/Bachem

        Agreement for Manufacture

        and Supply

    	
        Exhibit B

        Quality Assurance Plan 

         
	Gonadorelin

Acetate

 

See separate document

 

***

 

    	B-2

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

 

	
        Parnell/Bachem

        Agreement for Manufacture

        and Supply
	
        Exhibit C

        Sequence / Specification

         
	Gonadorelin

Acetate

 

“Product”
means Gonadorelin Acetate as a non-sterile active pharmaceutical ingredient in bulk form, manufactured under cGMP and released
against mutually agreed analytical methods having the following sequence:

 

	***	***	***
	***	***	***

***

 

    	C-1Exhibit 10.9

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***,
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

Supply Agreement for Pentosan Polysufate

 

Active Pharmaceutical Ingredient

 

Between

 

Parnell Manufacturing Pty Ltd

 

(ABN 46 138 251 582)

 

and

 

IDT Australia Limited

 

(ABN 66 066 522 970)

 

Effective Date: 3 December 2013

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

TABLE
OF CONTENTS

 

	 	 	 	 	Page
	 	 	 	 	 
	Article I	Interpretation	1
	 	 	 	 	 
	 	Section 1.1	Definitions	1
	 	Section 1.2	Other Definitions	4
	 	Section 1.3	Currency	4
	 	Section 1.4	Headings	4
	 	Section 1.5	Entire Agreement	4
	 	Section 1.6	Exhibits	4
	 	Section 1.7	Applicable Law	4
	 	 	 	 	 
	Article II	Term	5
	 	 	 	 	 
	 	Section 2.1	Term	5
	 	 	 	 	 
	Article III	Supply of Product	5
	 	 	 	 	 
	 	Section 3.1	Supply of Product	5
	 	Section 3.2	Manufacturing Services	5
	 	Section 3.3	Production Capacity	5
	 	Section 3.4	Processing Changes	5
	 	Section 3.5	Notice of Deviations	6
	 	Section 3.6	Subcontracting	6
	 	 	 	 	 
	Article IV	Forecasts 4.1 Rolling Forecasts	6
	 	 	 	 
	Article V	Testing and Samples	6
	 	 	 	 	 
	 	Section 5.1	Release Testing	6
	 	Section 5.2	Retained Samples	7
	 	Section 5.3	Stability Testing	7
	 	 	 	 	 
	Article VI	Purchase Orders	7
	 	 	 	 	 
	 	Section 6.1	Placement of Purchase Orders	7
	 	Section 6.2	Acceptance of Orders	7
	 	 	 	 	 
	Article VII	Shipment of Product	8
	 	 	 	 	 
	 	Section 7.1	Storage of Product	8
	 	Section 7.2	Release and Shipment of Product	8
	 	Section 7.3	Documentation	8
	 	 	 	 	 
	Article VIII	Acceptance of Shipments	8
	 	 	 	 	 
	 	Section 8.1	Acceptance of Shipments	8
	 	Section 8.2	Dispute of Rejected Product	9
	 	Section 8.3	Remedies	9
	 	Section 8.4	Destruction of Rejected Product	10
	 	 	 	 	 
	Article IX	Product Fees	10
	 	 	 	 	 
	 	Section 9.1	Fees	10

 

    	-i-

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	 	 	Page
	 	 	 	 	 
	 	Section 9.2	Adjustments to Fees	10
	 	Section 9.3	Taxes	11
	 	 	 	 	 
	Article X	Invoicing and Payment	11
	 	 	 	 	 
	 	Section 10.1	Issuance of Invoices	11
	 	Section 10.2	Invoice Contents	11
	 	Section 10.3	Payment of Invoices	11
	 	 	 	 	 
	Article XI	Intellectual Property	11
	 	 	 	 	 
	 	Section 11.1	Title	11
	 	Section 11.2	No Grant of Rights	12
	 	Section 11.3	Grant of License by Customer	12
	 	Section 11.4	No Use of Trademarks	12
	 	 	 	 	 
	Article XII	Confidentiality & Publicity	13
	 	 	 	 	 
	 	Section 12.1	Obligation of Confidentiality	13
	 	 	 	 	 
	Article XIII	Representations, Warranties and Covenants	14
	 	 	 	 	 
	 	Section 13.1	Supplier’s Representations, Warranties and Covenants	14
	 	Section 13.2	Customer’s Representations, Warranties and Covenants	15
	 	Section 13.3	Warranty Disclaimer	15
	 	 	 	 	 
	Article XIV	Indemnification	16
	 	 	 	 	 
	 	Section 14.1	Indemnification of Supplier	16
	 	Section 14.2	Indemnification of Customer	16
	 	Section 14.3	Indemnification Procedure	16
	 	 	 	 	 
	Article XV	Insurance	17
	 	 	 	 	 
	 	Section 15.1	Insurance Coverage	17
	 	Section 15.2	Evidence of Insurance	17
	 	 	 	 	 
	Article XVI	Legal and Regulatory	17
	 	 	 	 	 
	 	Section 16.1	Compliance with Laws	17
	 	Section 16.2	Maintenance of Records	17
	 	Section 16.3	Notice of Reports	17
	 	Section 16.4	Drug Master Files	18
	 	Section 16.5	Compliance with Regulatory Standards	18
	 	Section 16.6	Inspection	18
	 	 	 	 	 
	Article XVII	Recalls	18
	 	 	 	 	 
	 	Section 17.1	Safety	18
	 	Section 17.2	Recalls	18
	 	Section 17.3	Supplier’s Liability for Recall	19
	 	Section 17.4	Customer’s Liability for Recall	19

 

    	-ii-

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

TABLE OF CONTENTS

(continued)

 

	 	 	 	 	Page
	 	 	 	 	 
	 	Section 17.5	Replacement Shipments	19
	 	 	 	 	 
	Article XVIII	Termination	19
	 	 	 	 	 
	 	Section 18.1	Termination	19
	 	Section 18.2	Consequences of Termination	20
	 	Section 18.3	Return of Samples	20
	 	Section 18.4	Return of Confidential Information	20
	 	Section 18.5	Survival	20
	 	 	 	 	 
	Article XIX	Miscellaneous	21
	 	 	 	 	 
	 	Section 19.1	Assignment; Inurement	21
	 	Section 19.2	Counterparts; Facsimile	21
	 	Section 19.3	Dispute Resolution	22
	 	Section 19.4	Force Majeure	22
	 	Section 19.5	Further Assurances	22
	 	Section 19.6	Independent Contractors	22
	 	Section 19.7	Notices	23
	 	Section 19.8	Rights and Remedies	23
	 	Section 19.9	Severability	23
	 	Section 19.10	Waiver	23
	 	 	 	 	 
	Exhibit A – Description of Product	A-1
	 	 
	Exhibit B – Product Specification	B-1
	 	 
	Exhibit C – Fee Schedule	C-1
	 	 
	Exhibit D – Certificate of Analysis	D-1
	 	 
	Exhibit E – Quality Agreement	E-1

 

    	-iii-

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

THIS AGREEMENT dated
for reference the 3rd of December, 2013 (the “Effective Date”)

 

BETWEEN:

 

Parnell Manufacturing
Pty Ltd (ABN; 46 138 251 582), a corporation duly incorporated under the laws of New South Wales having an office at; 4 Century
Estate, 476 Gardner’s Road, Alexandria, NSW 2015 (“Customer”)

 

AND:

 

IDT Australia Ltd,
(ABN: 66 066 522 970), a corporation duly incorporated under the laws of Victoria having a place of business at 45 Wadhurst Drive,
Boronia, VIC 3155 (“Supplier”).

 

WHEREAS:

 

A.           Customer
is the owner of certain technology and patent rights regarding the Product having the description set out in Exhibit A (the “Product”,
as defined herein);

 

B.           Supplier
is engaged in process development, manufacturing and supply of active pharmaceutical ingredients (APIs); and

 

C.           Customer
desires that Supplier manufacture the Product, and Supplier desires to do so, on the terms and conditions set out in this Agreement.

 

NOW THEREFORE, in consideration
of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Article
I

Interpretation

 

Section 1.1           Definitions

 

In this Agreement the
following words and phrases shall have the following meanings:

 

“Affiliate”
of a party hereto means any entity which controls, is controlled by, or is under common control with such party. For purposes of
this definition, a party shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty
percent (50%) of the voting equity of the other entity (or other comparable ownership interest for an entity other than a corporation);

 

“Agreement”
means this Supply Agreement for the Product, including all Exhibits attached hereto;

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

“Confidential
Information” means all written information and data provided by the parties to each other hereunder and identified as
being “Confidential” and provided to the recipient, except that the term “Confidential Information” shall
not apply to any information or any portion thereof which:

 

(i)          was
known to the recipient or any of its Affiliates, as evidenced by its written records, before receipt thereof under this Agreement,

 

(ii)         is
disclosed to the recipient or any of its Affiliates, without restriction, after acceptance of this Agreement by a third person
who has the right to make such disclosure,

 

(iii)        is
or becomes part of the public domain through no breach of this Agreement,

 

(iv)        the
recipient can demonstrate is independently developed by or for the recipient or any of its Affiliates without use of or reliance
on the information disclosed under this Agreement, or

 

(v)         is
disclosed pursuant to the requirement or request of a governmental agency or Third Party to the extent such disclosure is required
by operation of law, regulation or court order and prompt notice is given by the recipient of such notice to the disclosing party
before making such disclosure.

 

The Confidential Information
may include, without limitation, data, know-how, formulae, processes, designs, sketches, photographs, plans, drawings, specifications,
samples, reports, studies, data, findings, inventions, ideas, production facilities, machines, production capacities, prices, market
share, research and development projects, and other market data. For the purposes of this Agreement, the DMF and Master Batch Record
shall be deemed the Confidential Information of Supplier.

 

“Drug Master
File” or “DMF” means a submission to any relevant regulatory authority that provides detailed information
about facilities, processes or methods used in the manufacture, processing, packaging and storing of a drug or excipient, among
others, in order to obtain regulatory approval for the production for that drug;

 

“Effective
Date” means the date set out on page one of this Agreement;

 

“APVMA”
means the Australian Pesticides and Veterinary Medicines Authority and any successor thereto;

 

“Fees”
means the fees specified in Exhibit C, as may be amended by the parties in accordance with this Agreement;

 

“cGMP”
Requirements” means: the current Good Manufacturing Practices standards required under ICH Q7 guideline;

 

“Improvements”
means, in relation to any Intellectual Property, any and all versions, adaptations, modifications, improvements, enhancements,
changes, revisions, translations and derivative works (whether complete or incomplete), of, to, in or based upon such Intellectual
Property;

 

    	2

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

“Intellectual
Property” means anything that is protected by any Rights in and to any and all patents, trade-marks, copyrights, industrial
designs, know-how and processes, and all other intellectual and industrial property Rights whatsoever and world-wide (whether registered
or unregistered and including Rights in any application for any of the foregoing);

 

“Manufacturing
Process” means the manufacturing instructions used for the manufacture of the Product;

 

“Master Batch
Record” means the complete detailed manufacturing instructions for the Manufacturing Process for the Product, as defined
by the Validation Protocol and cGMP Requirements, as may be amended from time to time; in accordance with cGMP Requirements, or
by mutual agreement of both Customer and Supplier.

 

“Materials”
means any and all, reagents, chemicals, compounds, physical samples, models, specimens and any other similar physical substances
that are used in the manufacture of the Product, including processes and activities leading up to and peripheral to the manufacture
of the Product;

 

“Notice of
Rejection” shall have the meaning ascribed thereto in Clause 8.1;

 

“Product”
means the API compound described in Exhibit A satisfying the Product Specifications;

 

“Product Specifications”
means the specifications set out in Exhibit B for the Product, as may be revised from time to time by mutual written agreement
of Customer and Supplier;

 

“Purchase
Order” has the meaning ascribed thereto in Clause 6.1;

 

“Quality Agreement”
shall mean the written agreement regarding pharmaceutical quality reached between Customer and Supplier respecting quality control
and quality assurance activities to be undertaken by Supplier in the performance of its duties hereunder and upon completion to
be attached hereto as Exhibit E.

 

“Recall”
means any action by Supplier, Customer or any of their respective Affiliates, to recover possession of the Product or finished
products containing the Product shipped to Third Parties. “Recalled” and “Recalling” shall
have comparable meanings;

 

“Rights”
shall mean any and all proprietary, possessory, use and ownership rights, titles and interests (whether beneficial or legal) of
all kinds whatsoever, howsoever arising, world-wide and whether partial or whole in nature;

 

“Seizure”
means any action by the APVMA or any other applicable governmental or regulatory agency in any jurisdiction, to detain or destroy
any Product or any intermediate or finished products containing the Product or prevent release of the Product or finished products
containing the Product. “Seized” and “Seizing” shall have comparable meanings;

 

“Term”
means the Initial Term and any Renewal Terms specified in Clause 2.1;

 

    	3

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

“Third Party”
means any party other than a party to this Agreement or an Affiliate of a party to this Agreement;

 

Section 1.2           Other
Definitions

 

Any words defined elsewhere
in this Agreement shall have the particular meaning assigned to the words.

 

Section 1.3           Currency

 

In this Agreement,
all references to money or payments means the currency of the Australia herein referred to as dollar or $ and all payments made
hereunder shall be made in that currency.

 

Section 1.4           Headings

 

The headings in this
Agreement are solely for convenience of reference and shall not be used for purposes of interpreting or construing the provisions
hereof.

 

Section 1.5           Entire
Agreement

 

This Agreement constitutes
the entire agreement between the parties concerning the subject matter hereof, and supersedes all written or oral prior agreements
or understandings with respect thereto, except for non-disclosure agreements. No party shall claim any amendment, modification,
or release from any provision hereof by mutual agreement, acknowledgement or acceptance or purchase order forms or otherwise, unless
in writing signed by an authorized representative of each party.

 

Section 1.6           Exhibits

 

The Exhibits attached
hereto shall be deemed to form an integral part of this Agreement. In the event of a conflict between the terms and conditions
set out in this Agreement and the terms and conditions set out in any Exhibit hereto or a Customer issued Purchase Order, the terms
and conditions set out in this Agreement shall govern except in the case of Exhibit E:  “Quality Agreement.”

 

Section 1.7           Applicable
Law

 

This Agreement shall
be governed by and construed in accordance with the Laws and Forum of Victoria, Australia. The parties acknowledge and agree that
the United Nations Convention on Contracts for the International Sale of Goods is specifically excluded from application to this
Agreement.

 

    	4

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article
II

Term

 

Section 2.1           Term

 

This Agreement shall
commence on the Effective Date and shall expire three (3) years from the Effective Date (“Initial Term”). This
Agreement shall automatically renew for successive three (3) year periods (a “Renewal Term”) commencing on the
expiration of the Initial Term or the preceding Renewal Term, as the case may be, unless either party delivers at least *** written
notice to terminate to the other party, as applicable or unless otherwise terminated early pursuant to the terms herein.

 

Article
III

Supply
of Product

 

Section 3.1           Supply
of Product

 

Supplier shall take
all necessary actions to manufacture and supply Product from the Effective Date of this Agreement. Supplier will be the non-exclusive
supplier and manufacturer of the Product and will supply to Customer or Customer’s designee, the Product, manufactured in
accordance with the Master Batch Record, the Product Specifications, the Quality Agreement and cGMP Requirements, in such quantities
as Customer has placed and Supplier has accepted Purchase Orders under Clauses 6.1 and 6.2. Supplier may supply Product in amounts
that are up to 5% more than the Purchase Order due to the inherently imprecise nature of manufacturing yields.

 

Section 3.2           Manufacturing
Services

 

Supplier will make
available its labour, equipment and facilities for the manufacture and characterization of the Product, including in-process and
quality control analysis, release testing, storage and bulk packaging and shipping of the Product, in accordance with the terms
and conditions of this Agreement. Supplier shall use its commercially reasonable efforts to comply with the delivery schedule as
agreed in the Purchase Order accepted by the Parties.

 

Section 3.3           Production
Capacity

 

Supplier agrees that
it shall provide to Customer 4 months written notice of any scheduled shutdown at its facilities that may impact Supplier’s
ability to manufacture and timely delivery of the Product to Customer under this Agreement.

 

Section 3.4           Processing
Changes

 

(a)          Once
a DMF has been lodged with the APVMA Supplier shall not make any regulatory changes to the Manufacturing Process that would impact
the APVMA’s acceptance of the quality and purity of the Product, the Master Batch Record or Product Specifications for the
manufacture of the Product, without the prior written consent of Customer, such consent shall not be unreasonably delayed or withheld.

 

    	5

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(b)          Customer
may request changes to the Manufacturing Process, Master Batch Record, the Product Specifications, storage, testing or analytical
methods or any starting materials for the manufacture of the Product, provided that any such changes which impact the cost of manufacturing
the Product inclusive of any process development, re-validation, scale-up and/or regulatory filings necessary to support such changes
will be reflected in a corresponding increase in the Fees paid by Customer under this Agreement. The notice of any such change
by Customer shall comply with the cGMP documentation system and SOPs maintained by Supplier at its production site.

 

(c)          In
the event of a change to the Manufacturing Process, Master Batch Record or the Product Specifications, the relevant documents and
related Exhibits to this Agreement will be revised accordingly.

 

(d)          All
operational Master Batch Records and SOP’s utilized by Supplier are to be in the English language.

 

Section 3.5           Notice
of Deviations

 

During the manufacture
of each batch of Product, Supplier shall provide to Customer prompt notice of deviations or non-conformities from the Manufacturing
Process, the Master Batch Record or the Product Specifications, as defined in the quality agreement between the parties.

 

Section 3.6           Subcontracting

 

Supplier shall obtain
Customer’s prior written approval to use a subcontractor to perform services under this Agreement. The subcontractor shall
be qualified according to the Supplier’s standard operating procedures. Any and all such contractors performing services
shall be subject to obligations of confidentiality and Intellectual Property no less restrictive than the terms herein.

 

Article
IV

Forecasts
4.1 *** Forecasts

 

Customer shall provide
to Supplier on a *** on or before the *** of *** during the Term, a *** forecast for the proceeding *** period commencing on the
*** of the following *** (“Forecast”). Within such *** Forecast, Customer will *** to provide a *** of the ***
of the *** by Customer for the ***.

 

Article
V

Testing
and Samples

 

Section 5.1           Release
Testing

 

Supplier shall perform
release testing of all batches of Product in accordance with the Product Specifications and the Master Batch Record, to determine
whether such batches of Product meet the requirements set out in the Product Specifications. Supplier shall ensure that:

 

    	6

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(a)          its
quality control or assurance department approves each batch of Product for release promptly following successful completion of
release testing; and

 

(b)          its
quality assurance department does not release any batch of Product that does not meet the requirements set out in the Product Specifications
without prior written consent of customer.

 

Supplier shall prepare
a Certificate of Analysis, in the form set out in Exhibit D, setting out the results of the release testing and which shall be
included with each batch of Product shipped to Customer.

 

Section 5.2           Retained
Samples

 

Supplier shall retain
and store in accordance with cGMP Requirements and Supplier’s internal quality standard operating procedures, retained samples
of each batch of Product manufactured under this Agreement.

 

Section 5.3           Stability
Testing

 

Customer shall be responsible
for performing all stability testing of the Product and shall ensure that all such testing is performed in compliance with the
applicable ICH regulations and be suitable for inclusion in the DMF. Supplier will provide adequate samples of manufactured Product
for use in stability testing in a timely manner.

 

Article
VI

Purchase
Orders

 

Section 6.1           Placement
of Purchase Orders

 

Section 6.2           Customer
shall place with Supplier *** purchase orders (the “Purchase Orders”), stating Customer’s ***, such ***not
to be ***of Purchase Order, for each delivery of Product to be made under this Agreement. Purchase Orders ***by *** without the
***. ***Purchase Orders shall be ***Acceptance of Orders

 

Supplier shall respond
to each Purchase Order placed by Customer under Clause 6.1 in writing, by electronic or other means, within a reasonable time,
not to exceed ten (10) business days after receipt of each Purchase Order, setting out Supplier’s acceptance of a Purchase
Order and Supplier’s ability to deliver the ordered Product in accordance with the Purchase Order. Subject to the availability
of raw materials, Supplier shall use commercially reasonable efforts to accommodate the requirements set out in each of Customer’s
Purchase Orders. Each Purchase Order is an offer to purchase the Product specified in the Purchase Order. Each Purchase Order will
upon Supplier giving written notification to Customer of Supplier’s acceptance of the Purchase Order, constitute a separate
binding contract between Supplier and Customer for the delivery by Supplier, and the purchase by Customer, of the Product specified
in the Purchase Order on the terms and conditions set out in this Agreement.

 

    	7

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article
VII

Shipment
of Product

 

Section 7.1           Storage
of Product

 

Supplier shall ensure
that all Product the subject of a Purchase Order given in accordance with Clause 6.1 will be held in storage in accordance with
the Product Specifications until shipped to Customer under this Agreement and that all storage areas meet cGMP Requirements. Supplier
will not be required to store Materials for a period greater than three (3) months.

 

Section 7.2           Release
and Shipment of Product

 

Supplier shall notify
Customer by electronic transmission of each batch of Product manufactured by it under this Agreement in accordance with this Clause
7 as soon as reasonably possible after Supplier’s quality assurance department approves the batch for release following successful
completion of the release testing procedures.

 

Supplier shall pack
and label shipping boxes and ship all orders of Product in a prompt and timely manner and in accordance with international transport
guidelines and regulations, the Product Specifications, and Customer’s reasonable written instructions for such shipment
and the terms of this Agreement.

 

The Product will be
sold FCA Supplier premises (as defined in Incoterms 2010). Title to Product shall remain vested in the Supplier and shall not pass
to the Customer until the Fees for the Product has been paid in full and monies received by the Supplier. Risk of loss or damage
of the Goods shall pass to Customer upon delivery to the common carrier.

 

Section 7.3           Documentation

 

Supplier shall include
with each shipment of Product shipped to Customer under Clause 7.2 commercially appropriate documentation; a Certificate of Analysis
for each batch of Product included in the shipment, in the form set out in Exhibit D; a copy of any investigation reports concerning
each batch of Product shipped (to be sent separately from shipment).

 

Article
VIII

Acceptance
of Shipments

 

Section 8.1           Acceptance
of Shipments

 

Customer or its designees
shall, within a period of thirty (30) calendar days (the “Acceptance Period”) after the date of physical receipt
of any shipment of Product from Supplier, inspect the Product for shortages, conduct testing and inspect the documentation to confirm
conformance with the applicable Product Specifications and provide Supplier with:

 

(a)          written
notice of any claim relating to any shortage in quantity of any shipment of Product; or

 

    	8

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(b)          written
notice to reject the Product (a “Notice of Rejection”), which shall include a description of the grounds for
rejection and copies of test reports and testing methodology conducted on the Product, if any.

 

Customer or its designees
may only reject a shipment of Product during the Acceptance Period on the grounds that the Product does not comply with the Product
Specifications. The parties agree that Product not validly rejected during the Acceptance Period is deemed accepted by the Customer.

 

Section 8.2           Dispute
of Rejected Product

 

Supplier may, at its
option, within 10 business days of receipt of any Notice of Rejection under Clause 8.1, challenge the Notice of Rejection by delivering
written notice thereof to Customer. In the event that Supplier challenges the Notice of Rejection, Customer and Supplier shall
conduct a joint investigation. If Supplier and Customer are unable to resolve the issue of non-compliance then a sample of the
materials that have been retained by Supplier and by Customer will be submitted to an independent laboratory (acceptable to both
parties) for testing against the Product Specifications, and determination whether or not the non-compliance may be caused by a
fault on the part of Supplier. The test results of the independent laboratory testing shall be final and binding upon Customer
and Supplier, and the fees and expense of such laboratory testing shall be borne entirely by the party against whom such laboratory’s
findings are made.

 

Section 8.3           Remedies

 

(a)          In
the event of a Product shortage, Customer’s sole and exclusive remedy will be for Supplier to make up the shortage by delivering
additional quantities of the Product, at no additional cost to Customer, within ***after receiving such notice; or at the Customer’s
sole election’

 

(b)          In
the event that Customer issues a timely Notice of Rejection in respect of any shipment of Product:

 

(i)          if
Supplier does not challenge the Notice of Rejection, Customer’s sole and exclusive remedy shall be for:

 

(1)         Supplier
to replace the shipment of rejected Product with conforming Product at no additional cost to Customer within ***after receiving
such notice; or at the Customer’s sole election;

 

(2)         Supplier
to rework the Product, or return or credit the Fees paid or due by Customer for that Product.

 

(ii)         if
Supplier does challenge the Notice of Rejection and:

 

(1)         the
joint investigation conducted under Clause 8.2 supports Customer’s rejection of the Product and finds that the nonconformity
is due to the actions of Supplier, 8.3(a) shall apply accordingly; or

 

    	9

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(2)         if
the joint investigation conducted under Clause 8.2 does not support Customer’s rejection of the Product, Customer shall be
deemed to have accepted the Product. The same shall apply in the case that such investigation supports Customer’s rejection
of the Product, but does not support the finding that the non-conformity is due to the actions of Supplier.

 

The relief provided
by this Clause 8.3 shall be the sole and complete remedy available to Customer with respect to any shortage of Product or any validly
rejected Product unless the Supplier fails to manufacture replacement Product within ***as directed by this clause 8.3.

 

Section 8.4           Destruction
of Rejected Product

 

The party in possession
of any rejected Product which does not comply with the Product Specifications or cGMP Requirements shall destroy, in accordance
with all applicable laws and regulations and in a manner to which Customer has given its prior written approval, all rejected Product
in its possession, but only after the parties have followed the procedures specified under Clauses 8.2 and 8.3. No rejected Product
shall be sold, reprocessed, salvaged, reclaimed or otherwise reused in any manner by Supplier or Customer with the exception of
use testing and analysis by Supplier in investigation of rejected Product cause. Representatives of the party not performing the
destruction shall be permitted to witness the destruction of the rejected Product under this Clause. Such travel to be at each
parties own cost

 

Article
IX

Product
Fees

 

Section 9.1           Fees

 

Customer shall pay
to Supplier, in respect of each Purchase Order placed by Customer, the applicable Fees for the supply of the Product under this
Agreement, in accordance with the terms of this Agreement and Exhibit C.

 

Section 9.2           Adjustments
to Fees

 

(a)          Commencing at the first anniversary of the Effective date and then ***thereafter, the parties hereby agree
that the Supplier may increase the Fees ***  If the Supplier wishes to increase the then current Fees by more than 2.5% per
year, the Supplier may request to renegotiate the Fees with the Customer.  Such request may not occur more than once every
12 months and must set out the reasons for such request to increase the Fees including one of the following events:

 

(i)          the
*** component of the Fees ***

 

(ii)         Supplier’s
***.

 

(b)          The
Supplier will notify the Customer of any change in the Fees *** by more than 2.5% not later than the anniversary of the Effective
Date prior to the increase taking effect.

 

    	10

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(c)          In
the case of a Fee increase *** on receipt of such notification, the parties shall seek in good faith, to agree an adjustment to
the Fees, ***.

 

Section 9.3           Taxes

 

The ***applicable to
the supply of the Product under this Agreement (“Taxes”).

 

Article
X

Invoicing
and Payment

 

Section 10.1         Issuance
of Invoices

 

Supplier shall invoice
Customer for each Purchase Order accepted under Clause 6.2 on the day of release under Clause 7.2 for the actual amount of Product
shipped.

 

Section 10.2         Invoice
Contents

 

(a)          All
invoices issued by Supplier under Clause 10.1 shall show:

 

(i)          the
actual quantity of Product shipped;

 

(ii)         the
lot number of each batch of Product shipped;

 

(iii)        the
Fees for the quantity of Product shipped, based on the Fees for the Product set out in the applicable Purchase Order;

 

(iv)        the
Purchase Order number placed by Customer for the Product shipped.

 

(b)          If
Customer disputes for any reason the amount of any invoice submitted by Supplier, Customer shall notify Supplier of such dispute
within 10 calendar days after the date of the invoice, and the parties shall promptly attempt to resolve the dispute.

 

Section 10.3         Payment
of Invoices

 

Each invoice provided
by Supplier to Customer under Clause 10.1 shall be paid by Customer to Supplier within ***after ***, provided that Customer has
not reasonably disputed the invoice. All payments will be made *** directly to the Supplier account as specified in the respective
Invoice.

 

Article
XI

Intellectual
Property

 

Section 11.1         Title

 

The parties agree that
each respective Party does and will continue to own all Rights in and to their Intellectual Property and Confidential Information
in existence prior to the commencement of the Agreement. The Parties hereby agree that any Improvements to the manufacturing process
of the Product or analytical methods used in the manufacture or characterization of the Product which are made solely as a result
of the transfer of Intellectual Property or Confidential Information by the Customer to the Supplier and which were not already
known by the Supplier may only be used by Supplier in the manufacture of the Product for the Customer and such use will cease upon
termination of this Agreement. Subject to the foregoing, any Improvements to the manufacturing process of the Product made by Supplier
will be owned by the Supplier.

 

    	11

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Section 11.2         No
Grant of Rights

 

Except as otherwise
provided herein, neither party hereto shall be deemed by this Agreement to have been granted any Rights of the other party.

 

Section 11.3         Grant
of License by Customer

 

(a)          During
the Term, Customer, or its sub-licensee hereby grants to Supplier a paid-up, royalty-free, non-exclusive license, without the right
to sublicense, to Customer’s Confidential Information and the Intellectual Property reasonably necessary to manufacture and
supply to Customer the Product hereunder, but only for such purposes.

 

(b)          The
parties agree that the grant of license contained in this Clause 11.3 is personal to Supplier only and shall be exercised by Supplier
only and Supplier agrees to make use of Customer’s Confidential Information and Intellectual Property only in accordance
with this license and only by Supplier.

 

(c)          The
parties agree that supply of the Product as specified under this Agreement by the Supplier to the Customer shall be exclusive and
Supplier will not sell or offer to sell or allow any associated company or related entity to manufacture or sell the Product to
any Third Party.

 

(d)          Nothing
in this Agreement shall preclude or limit Supplier from providing services or developing materials for itself or other customers,
or from utilizing the general knowledge gained during the course of its proper performance hereunder. The Parties agree that Supplier
is under no obligation to utilize the Intellectual Property or Confidential Information of the Customer.

 

Section 11.4         No
Use of Trademarks

 

Nothing contained herein
shall give either party any right to use any trademark of the other party. All trademarks and service marks adopted by Customer
to identify the Product are and shall remain the property of Customer.

 

    	12

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article
XII

Confidentiality
& Publicity

 

Section 12.1         Obligation
of Confidentiality

 

(a)          Each
party (Recipient) must keep confidential the other party’s (Disclosing Party’s) Confidential Information. A Recipient
may only disclose the Disclosing Party’s Confidential Information, for the purpose of performing its obligations under this
Agreement, to:

 

(i)          officers,
employees, accountants, auditors, legal advisers and other professional advisers (approved by the Disclosing Party to receive Confidential
Information) of the Recipient, or officers and employees any person with whom the Recipient has a confidentiality agreement that
imposes on that person confidentiality obligations no less stringent than those imposed on Recipients under this Agreement, who:

 

(1)         have
a need to know (and only to the extent that each has a need to know); and

 

(2)         have
been directed and have agreed to keep confidential the Confidential Information on terms consistent with this Agreement; or

 

(3)         to
the extent, and to the persons, required by Law or an applicable regulatory body.

 

(b)          A
Recipient must, at its own expense:

 

(i)          ensure,
at all times, that each officer, employee and subcontractor to whom the Disclosing Party’s Confidential Information has been
disclosed under this Clause 12.1 keeps that information confidential;

 

(ii)         establish
and maintain effective security measures to safeguard the Disclosing Party’s Confidential Information from unauthorized access
or use;

 

(iii)        keep
the Disclosing Party’s Confidential Information under its control (whether it has physical possession of the Confidential
Information or not);

 

(iv)        immediately
take all steps to prevent or stop, and comply with any direction issued by the Disclosing Party from time to time regarding, a
suspected or actual breach; and

 

(v)         immediately
notify the Disclosing Party of any suspected or actual unauthorized use, copying or disclosure of the Disclosing Party’s
Confidential Information.

 

(c)          each
party will provide assistance reasonably requested by the other party in relation to any proceedings that party may take against
any person (other than the other party) for unauthorized use, copying or disclosure of the party’s Confidential Information.

 

    	13

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(d)          each
party acknowledges that it is aware that any breach of this Clause 12.1 may result in damage to the other party and that each party
is entitled to enforce its rights by specific performance or injunction proceedings as monetary damages may not be sufficient relief.

 

(e)          On
termination of this Agreement, each Recipient agrees that:

 

(i)          it
must continue to keep confidential in accordance with this Clause 12.1 the Disclosing Party’s Confidential Information until
it ceases to be Confidential Information pursuant to Clause 1.1 above; and

 

(ii)         its
rights to use and disclose the Disclosing Party’s Confidential Information cease other than in relation to information which
the Recipient is required to disclose in order to comply with any reporting obligations to relevant regulatory bodies.

 

(iii)        Subject
to a party’s obligation to comply with stock exchange rules or other governmental requirements, neither party will make any
public statements about this Agreement, the Product or its relationship with the other party without the other party’s prior
written approval such approval shall not be unreasonably delayed or withheld.

 

(iv)        All
references in this Clause to the “Disclosing Party” or the “Disclosing Party’s Confidential Information”
apply to a third party whose Confidential Information is used in the performance of, or is necessary to the supply of the Products
as if the third party was a party to this Agreement.

 

Article
XIII

Representations,
Warranties and Covenants

 

Section 13.1         Supplier’s
Representations, Warranties and Covenants

 

Supplier hereby represents,
warrants and covenants to Customer as follows:

 

(a)          Supplier
has been duly organized and is validly subsisting and in good standing in its jurisdiction of organization;

 

(b)          Supplier
has the right to enter into this Agreement and this Agreement is a legal and valid obligation binding upon Supplier and enforceable
in accordance with its terms;

 

(c)          Supplier
has not made and will not knowingly make any commitments to Third Parties inconsistent with or in derogation of Supplier’s
obligations under this Agreement and Supplier is not subject to any obligations that would prevent it from entering into or carrying
out its obligations under this Agreement;

 

    	14

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(d)          All
Product delivered to Customer under this Agreement will have been manufactured in a competent fashion in accordance with the Product
Specifications and cGMP Requirements by qualified personnel;

 

(e)          Supplier’s
facilities, including equipment, systems, utilities and services, comply with cGMP Requirements for the manufacture of the Product
under this Agreement; and

 

(f)          All
records and reports required to be maintained by Supplier under cGMP Requirements shall be accurate and complete in all material
respects.

 

Section 13.2         Customer’s
Representations, Warranties and Covenants

 

Customer hereby represents,
warrants and covenants to Supplier as follows:

 

(a)          Customer
has been duly organized and is validly subsisting and in good standing in its jurisdiction of organization and has the power to
carry on the business as now being conducted by it;

 

(b)          Customer
has the right to enter into this Agreement and this Agreement is a legal and valid obligation binding upon Customer and enforceable
in accordance with its terms;

 

(c)          Customer
has not made and will not make any commitments to Third Parties inconsistent with or in derogation of Customer’s obligations
under this Agreement and Customer is not subject to any obligations that would prevent it from entering into or carrying out its
obligations under this Agreement; and

 

(d)          To
the best of the Customer’s knowledge all Intellectual Property and Confidential Information provided to the Supplier under
this Agreement does not infringe any rights of a Third Party.

 

Section 13.3         Warranty
Disclaimer

 

Except for the warranties
provided in section 13, neither party makes any warranty, expressed or implied by statute or in writing, regarding the services
or the Product, including without limitation any warranty regarding their fitness for purpose, their quality, their merchantability
or their non-infringement of intellectual property rights of third parties. Any other representations or warranties made by any
person or entity, including employees or representatives of a party hereto, that are inconsistent herewith, shall be disregarded
and shall not be binding on such party. Notwithstanding anything to the contrary herein, in no event shall either Party be liable
for any incidental or consequential damages; furthermore the Parties hereby agree that the Supplier’s maximum liability under
this Agreement shall be limited to the Fees paid pursuant to this Agreement.

 

    	15

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article
XIV

Indemnification

 

Section 14.1         Indemnification
of Supplier

 

Subject to the limitation
of liability provided in Clause 13.3, Customer shall indemnify and hold Supplier and its officers, directors, agents, servants,
and employees harmless against any and all actions, claims, demands, proceedings, suits, losses, damages, costs and expenses (including
reasonable legal fees on a solicitor client basis) (in this Clause, “Claims”) of any Third Party, including
all Claims for personal injury or death, arising from the use, sale or commercialization of the Product, Claims that Supplier’s
use of Customer’s Confidential Information or Intellectual Property knowingly infringes the rights of a Third Party, or Claims
arising out of Customer’s breach of its obligations under this Agreement, and which is not attributable to the gross negligence
or willful misconduct of Supplier or its officers, directors, agents, servants, employees, students or contractors.

 

Section 14.2         Indemnification
of Customer

 

Subject to the limitation
of liability provided in Clause 13.3, Supplier shall indemnify and hold Customer and its officers, directors, agents, servants,
employees and consultants harmless against any and all Claims of any Third Party, including all Claims for personal injury or death
directly arising from the manufacture by Supplier of the Product, or Claims arising out of Supplier’s breach of its obligations
under this Agreement, and which is not attributable to the gross negligence or willful misconduct of Customer or its officers,
directors, agents, servants, employees or contractors.

 

Section 14.3         Indemnification
Procedure

 

The indemnities contained
in this Clause 14 shall be conditional on compliance with the terms and conditions set out in this Clause 14.3. The indemnifying
party will defend, contest, or otherwise protect against any such Claims at its own cost and expense provided that prompt written
notice is given, of any Claims for which indemnification might be claimed. The indemnified party may, but will not be obligated
to, participate at its own expense in a defense thereof by counsel of its own choosing, but the indemnifying party shall be entitled
to control the defense unless the indemnified party has relieved the indemnifying party from liability with respect to the particular
matter. If the indemnifying party fails to timely defend, contest, or otherwise protect against any such Claims, the indemnified
party may, but will not be obligated to, defend, contest, or otherwise protect against the same, and make any reasonable compromise
or settlement thereof and recover the entire costs thereof from the indemnifying party, including reasonable legal fees and costs
and disbursements, and all amounts paid as a result of such Claims or the compromise or settlement thereof, provided, however,
that if the indemnifying party undertakes the timely defense of such matter, the indemnified party shall not be entitled to recover
from the indemnifying party for its costs incurred in the defense thereof. The indemnified party shall cooperate and provide such
assistance as the indemnifying party may reasonably request in connection with the defense of the matter subject to indemnification.
No settlement that will impact the other party’s business will be made without prior written approval of the other party.

 

    	16

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Article
XV

Insurance

 

Section 15.1         Insurance
Coverage

 

Customer and Supplier
each represent that they are sufficiently insured against any liability arising under Clause 14. Customer and Supplier each represent
that they are sufficiently insured against any liability arising under this Agreement.

 

Section 15.2         Evidence
of Insurance

 

Each of Customer and
Supplier shall, upon written request by the other, provide the other party with a copy of all insurance policies maintained under
this Clause 15 relating to the manufacture of the Product in bulk quantities and the facilities therefore.

 

Article
XVI

Legal
and Regulatory

 

Section 16.1         Compliance
with Laws

 

(a)          Each
party shall in connection with its obligations, rights and duties under this Agreement and in the manufacturing, handling, loading,
shipping, using, commercializing, reselling and distributing the Product:

 

(i)          comply
with all applicable local: laws, rules, regulations or other requirements applicable to each party’s business and

 

(ii)         obtain
and maintain in full force and effect all applicable licenses, permits, certificates, authorizations or approvals from local governmental
authorities necessary to conduct its business and the activities contemplated under this Agreement.

 

Section 16.2         Maintenance
of Records

 

Supplier shall maintain
adequate books and records consistent with cGMP Requirements and any other applicable laws and requirements of applicable local
governmental or regulatory authorities, in respect of test records, samples and associated support data for all batches of Product
manufactured sufficient to substantiate and verify Supplier’s duties and obligations under this Agreement for five (5) years
from the date of manufacture of the respective Product batch.

 

Section 16.3         Notice
of Reports

 

Supplier shall provide
to Customer within ten (10) Business Days of receipt by Supplier copies of all portions of any reports of any local governmental
or regulatory authority which may impact on the manufacture or testing of the Product, including, without limitation, any APVMA
audit observations, APVMA warning letters or other correspondence from the APVMA or equivalent regulatory authority correspondence.

 

    	17

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Section 16.4         Drug
Master Files

 

At the ***, ***shall
be responsible for:

 

(a)          the
preparation of a Drug Master File for the Product in a format acceptable to the local regulatory authorities. The DMF shall be
produced following ***that the ***under this Agreement is ***; and

 

(b)          after
initial approval of the local DMF, ***and ***to maintain the DMF relating to the ***at the ***. Subject to this Clause 16.3, ***with
its filing of any application, in the territory(s) where the Product ***, with the ***.

 

Section 16.5         Compliance
with Regulatory Standards

 

(a)          Supplier
shall be responsible for manufacturing the Product in compliance with cGMP Requirements and the standards of any other applicable
governmental or regulatory authority.

 

(b)          Each
party will provide reasonable assistance to the other, at no charge, if necessary to respond to audits, inspections, inquiries,
or requests of the regulatory authorities. Supplier shall advise Customer immediately if Supplier receives notice of an impending
inspection or if an authorized agent of the APVMA or other relevant governmental agency visits any of Supplier’s manufacturing
facilities concerning the Product.

 

Section 16.6         Inspection

 

Supplier shall allow
one annual inspection or audit as provided for in the Quality Agreement. Customer shall provide to Supplier not less than sixty
(60) days written notice regarding a request for an annual inspection or audit.

 

Article
XVII

Recalls

 

Section 17.1         Safety

 

Supplier shall provide
Customer with reasonable co-operation to help Customer investigate adverse events involving the manufacture of the Product. The
cost and expense of any testing undertaken by Supplier at Customer’s request shall be borne by Customer.

 

Section 17.2         Recalls

 

(a)          If
either party has grounds to implement a Recall, the party recommending such Recall shall immediately notify the other party in
writing of such grounds.

 

(b)          Subject
to the applicable law, Customer and its designees shall have the sole responsibility to implement any Recall of the Product or
any intermediate or finished product containing the Product.

 

    	18

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(c)          Supplier
shall reasonably cooperate with Customer and its designees in implementing any such Recall

 

Section 17.3         Supplier’s
Liability for Recall

 

In the event of a Recall
or Seizure arising from a negligent action or material breach of this Agreement by the Supplier, then in such case the Supplier
shall refund the Fees paid by Customer for any Recalled Product including any such Product that cannot be shipped due to the Recall.

 

Section 17.4         Customer’s
Liability for Recall

 

In the event of a Recall
or Seizure arising from a negligent action or material breach of this Agreement by the Customer, then in such case the Customer
shall reimburse Supplier for any cost reasonably expended by Supplier in connection with the Recall.

 

Section 17.5         Replacement
Shipments

 

In the event of any
Recall or Seizure with respect to the Product, Supplier shall, unless otherwise directed by Customer, as soon as reasonably possible,
supply replacement Product to Customer in an amount sufficient to replace the amount of Product Recalled or Seized.

 

Article
XVIII

Termination

 

Section 18.1         Termination

 

In addition to any
other entitlement to terminate this Agreement early, this Agreement may be terminated:

 

(a)         by
either party providing three (3) months written notice; or

 

(b)         immediately,
by either party providing written notice if the other party makes a general assignment for the benefit of creditors, or if a petition
in bankruptcy or under any insolvency law is filed by or against the other party and such petition is not dismissed within 60 calendar
days after it has been filed; or

 

(c)         immediately,
by either party providing written notice of a breach of any material provision of this Agreement by the other party and the breach
is not cured within 60 calendar days; or

 

(d)         immediately,
by either party providing written notice to the other in the event any governmental law, regulation or order is adopted and made
effective which would make performance of such party’s obligations under this agreement impossible or commercially impracticable.

  

    	19

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Section 18.2         Consequences
of Termination

 

(a)          On
expiration or earlier termination of this Agreement, both parties shall be released from all obligations and duties imposed or
assumed hereunder, except for any outstanding obligations and duties relating to *** or ***.

 

(b)          all
Rights granted by Customer to Supplier under Clause 11 shall immediately revert to Customer and may not be used or exploited in
any manner thereafter by Supplier except that Supplier may continue to use any such Rights in order to fulfill its surviving obligations
under Clause 18 and only for such purpose.

 

(c)          ***by
the ***but *** at the ***will ***, subject to the terms and conditions herein.

 

Section 18.3         Return
of Samples

 

On expiration or earlier
termination of this Agreement, unless otherwise instructed by Customer, Supplier shall, within ***, return to Customer all Samples
or other supplies of the Product in its possession or control in any form unless the samples are required by regulations to be
retained by the Supplier. The cost of returning any such supplies shall:

 

(a)          in
the event of expiration or termination of this Agreement, ***; and

 

(b)          in
the event of early termination for breach, ***.

 

Section 18.4         Return
of Confidential Information

 

On expiration or earlier
termination of this Agreement, unless otherwise agreed between the parties, each party shall:

 

(a)          promptly
cease all use of the Confidential Information of the other party and ensure that its corporate counsel, employees and contractors
cease all use thereof; and upon written request of the other party;

 

(i)          return
to the other party all original copies of the Confidential Information of the other party in its control or possession; and subject
to the retention of one (1) complete copy for archival purposes and to satisfy any applicable legal requirements; and

 

(ii)         destroy
any and all copies or other reproductions or extracts of the Confidential Information of the other party and all other documents,
computer files, memoranda, notes or other writings prepared based on such Confidential Information subject to 18.3(a)(i).

 

Section 18.5         Survival

 

(a)          Expiration
or early termination of this Agreement shall not relieve either party of:

 

    	20

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

(i)          its
obligations incurred prior to such expiration or early termination

 

(ii)         the
obligation for Supplier to manufacture and deliver the Product under Purchase Orders placed by Customer and accepted by Supplier
prior to the effective date of expiration or notice date of termination

 

(iii)        the
obligation for Customer to accept and pay for Product manufactured and delivered under Purchase Orders placed by Customer and accepted
by Supplier prior to the effective date of expiration or earlier termination except if Customer validly rejects said shipment pursuant
to Clause 8.1

 

(b)          In
addition, the following provisions shall survive any expiration or early termination of this Agreement:

 

(i)          Clause
1 (Interpretation) ; Clause 5.2 (Retained Samples); Clause 11 (Intellectual Property); Clause 12 (Confidentiality); Clause 13.3
(Warranty Disclaimer); Clause 14 (Indemnification); Clauses 17.2 (Recalls), 17.3 (Supplier’s Liability for Recalls) and 17.4
(Customer’s Liability for Recalls); Clause 18.2 (Consequences of Termination); Clauses 18.3 (Return of Samples), 18.4 (Return
of Confidential Information) and 18.4 (Survival); and Clause 19 (Miscellaneous).

 

Article
XIX

Miscellaneous

 

Section 19.1         Assignment;
Inurement

 

(a)          This
Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their successors and permitted assigns.
Supplier shall not assign this Agreement, in whole or in part, to any person without the prior written consent of Customer, except
to a third party which acquires all, or substantially all, of Supplier’ business or assets, whether through merger or otherwise.

 

(b)          Customer
shall be entitled to assign this Agreement, in whole or in part, to any third party without the consent of Supplier, provided that
Customer remains liable for any payments Supplier is or will be entitled to as compensation for Supplier’ Services and deliveries
from orders agreed to between Customer and Supplier under this Agreement prior or subsequent to the effective date of Customer’s
assignment unless such payments are effected to Supplier by any of such third party

 

Section 19.2         Counterparts;
Facsimile

 

This Agreement may
be executed in any number of counterparts (either originally or by electronic transmission), each of which shall be deemed to be
an original and all of which taken together shall be deemed to constitute one and the same instrument.

 

    	21

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Section 19.3         Dispute
Resolution

 

Any controversy or
claim arising out of or relating to this Agreement, or the breach thereof, shall be notified in writing to the other party and
thereupon referred to senior management of the parties for amicable resolution. In the event that amicable resolution has not been
achieved within 21 days, then the dispute shall be referred to mediation. The parties agree that such mediation shall be conducted
in Melbourne by a single Institute of Mediators and Arbitrators Australia mediator, agreeable to both parties.

 

Section 19.4         Force
Majeure

 

(a)          If
either party is prevented from, or impeded in, performing any of its obligations under this Agreement due to a Force Majeure Event,
it must promptly give notice to the other party specifying:

 

(i)          the
circumstances constituting the Force Majeure Event; and

 

(ii)         the
extent and likely duration of those circumstances.

 

(b)          If
a party gives a notice under this Clause 19.4, the party’s obligations under this Agreement, will be suspended for as long
as the Force Majeure Event may continue to prevent it from, or impede it in, performing any of its obligations under this Agreement.

 

(c)          If
there is a Force Majeure Event, a party must:

 

(i)          make
every reasonable effort to minimize the effects of the Force Majeure Event; and

 

(ii)         use
reasonable efforts to overcome the Force Majeure Event; and

 

(iii)        promptly
resume performance of its obligations under this Agreement as soon as reasonably possible after cessation of the Force Majeure
Event.

 

(d)          If
performance is affected for a cumulative period of more than six (6) months in any 12 month period, a party may terminate this
Agreement by notice in writing to the other party.

 

Section 19.5         Further
Assurances

 

The parties shall both
execute and deliver such further instruments and do such further acts as may be required to implement the intent of this Agreement.

 

Section 19.6         Independent
Contractors

 

Supplier and Customer
shall be independent contractors and shall not be deemed to be partners, joint venturers or each other’s agents under this
Agreement, and neither party shall have the right to act on behalf of the other except as is expressly set forth in this Agreement.

 

    	22

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Section 19.7         Notices

 

Unless otherwise provided
herein, a notice given under this Agreement shall be in writing and sent by (i) overnight courier, (ii) fax with a confirmation
copy, (iii) electronic mail reasonably indicating successful transmission on the sender’s system, or (iv) by other means
of delivery requiring a written acknowledged receipt. A notice serviced on a Saturday, Sunday or public holiday in the place of
delivery is deemed to be served on the next business day.

 

	If to Supplier	If to Customer
	 	 
	 	 

 

Either party may change
the address to which any Correspondence to it is to be addressed by notification to the other party as provided herein.

 

Section 19.8         Rights
and Remedies

 

The rights and remedies
available under this Agreement shall be cumulative and not alternative and shall be in addition to and not a limitation of any
rights and remedies otherwise available to the parties at law or in equity.

 

Section 19.9         Severability

 

If any term or provision
of this Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as
if such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been
contained herein.

 

Section 19.10         Waiver

 

No waiver or modification
of any of the terms of this Agreement shall be valid unless in writing and signed by an authorized representative of the parties
hereto. Failure by any party to enforce any rights under this Agreement shall not be construed as a waiver of such rights, nor
shall a waiver by any party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances.

 

    	23

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

IN WITNESS WHEREOF,
each of the parties hereto has caused this Agreement to be executed by its duly authorized officer as of the dates set forth below.

 

	PARNELL MANUFACTURING PTY LTD	 
	 	 
	by its authorized signatory:	 
	 	 	 
	/s/ Robert Joseph	 
	Name:	Robert Joseph	 
	Title:	CEO	 
	Date:	4 December 2013	 
	 	 	 
	IDT AUSTRALIA LIMITED	 
	 	 
	by its authorized signatory:	 
	 	 
	/s/ Paul D R MacLeman	 
	Name:	Dr. Paul D R  MacLeman	 
	Title:	Managing Director	 
	Date:	3 December 2013	 

 

    	24

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

Exhibit A - Description of Product

 

Common Name: Sodium
Pentosan Polysulfate API

 

The substance is referred to as “PPS”
on all internal documentation.

 

***

***

 

    	A-1

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit B - Product Specifications

 

***

	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	 	 	 	 	 
	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	 	 	 	 	 
	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	***	 	***	 	***
	***	 		 	***
	 	 	 	 	***
	 	 	***	 	***
	 	 	 	 	***
	 	 	 	 	***
	 	 	 	 	***
	***	 		 	***
	 	 	 	 	***
	 	 	***	 	***
	 	 	 	 	***
	 	 	 	 	 
	***	 	***	 	***
	 	 	 	 	***
	***	 	***	 	***

***

    	B-1

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit C - Fee Schedule

 

Customer agrees to
the following:

 

The Fee ***of the Product
will be:

 

i.            For
Purchase Orders of ***For Purchase Orders of ***

 

ii.         Purchase
Orders in ***will only be ***to the ***.

 

    	C-1

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit D - Certificate of Analysis

 

***

	***
	***
	***
	***
	***
	***
	***
	***
	***
	***
	***
	***
	***
	***
	***
	***

 

    	D-1

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION,
WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit E Quality Agreement

 

The Quality Agreement
as executed between the parties on ________ 2013 is incorporated herein by reference, including any amendments thereto as may be
mutually agreed between the parties in writing.

 

    	E-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]